Novo Nordisk at a Crossroads: Reimbursement Milestones and Pipeline Data Collide with Pricing and Formulary Headwinds

Novo Nordisk stock claws back from March low but faces pricing pressure in North America, reimbursement wins in Europe and India, and key CagriSema data at ADA June 5-8.

Novo Nordisk’s share price has clawed back from a March low of €30.48 to around €39, but the 36% annual decline tells a different story. The Danish drugmaker is fighting on multiple fronts: rising reimbursement opportunities in Europe and India are tempered by intensifying pricing pressure in North America and a crucial pipeline test next month.

France will become the first European Union member to reimburse weight-loss drugs from mid-June 2026. Wegovy and Eli Lilly’s Mounjaro will be covered for around one million severely obese patients — those with a BMI of 40 or higher, or 35 with relevant comorbidities. The standard reimbursement rate is 65%, though most eligible patients are expected to receive full coverage due to underlying conditions. Previously, patients paid roughly €300 out of pocket each month. The programme will cost the French health system an estimated €100 million annually.

India has also provided a regulatory boost. The country’s CDSCO has approved Wegovy for adolescents aged 12 and older weighing over 60 kilograms, a target group where Eli Lilly’s Mounjaro currently lacks authorisation.

Yet in the United States, the competitive landscape is shifting against Novo Nordisk. CVS Health’s Caremark unit will add Lilly’s Zepbound back to its formulary from October 2026 and also include Lilly’s new oral pill Foundayo from June. For 25 to 30 million CVS-insured patients, Wegovy and Lilly’s products will now be on equal footing, stripping Novo Nordisk of its former preferential status.

Pricing pressure extends well beyond formulary changes. In Canada, GLP-1 drugs are already discounted by 40-65%. The US government’s “TrumpRx.gov” initiative is pursuing a most-favoured-nation model that explicitly targets Ozempic. Deutsche Bank rates the stock a “Hold” with a 290 Danish krone price target, citing mounting pricing headwinds in international markets.

With these pressures in the background, all eyes are on Novo Nordisk’s upcoming clinical data presentation at the American Diabetes Association (ADA) Scientific Sessions in New Orleans from June 5-8. The company plans to unveil 40 abstracts, including phase 3 results from the REIMAGINE-1, -2, and -3 trials for CagriSema — a fixed-dose combination of a long-acting amylin analogue and semaglutide being tested in type 2 diabetes for both blood sugar control and weight loss. CagriSema has its own symposium on June 7, the same day as Novo Nordisk’s R&D investor day webcast.

Additional phase 2 data will be released for Zenagamtide (formerly Amycretin), a once-weekly injectable GLP-1 and amylin receptor agonist being developed for obesity and type 2 diabetes, in both subcutaneous and oral formulations. The ADA presentations also include new readouts for Ozempic, Wegovy, IcoSema, and efruxifermin.

The urgency behind these pipeline updates is underscored by the company’s first-quarter 2026 financial results. Net sales reached nearly 96.8 billion Danish kroner, up 24% year on year, while operating profit jumped 54% to roughly 59.6 billion kroner. Novo Nordisk raised its full-year guidance. However, excluding one-off effects from the US 340B drug pricing programme, revenue and operating profit fell 4% and 6% respectively at constant exchange rates. The underlying weakness makes the path to future growth heavily dependent on pipeline success.

Novo Nordisk has been careful to note that CagriSema, Zenagamtide, IcoSema, and efruxifermin are not approved in the US and that safety and efficacy have not been fully established. That puts the debate squarely on data quality rather than premature commercialisation fantasies. The June presentations will reveal whether the company can credibly build a broader cardiometabolic platform — or whether the gap to Eli Lilly, which has gained roughly 57% over the same period, will persist.